Jubilant Pharmova reports dip in its net profit by 71% for Q1FY23

Jubilant Pharmova reported total income of INR 1,452 crores during the period ended June 30, 2022 as compared to INR 1,635 crores during the period ended June 30, 2021 depicting a dip of 11% while the net profit further plummeted by 71% as the company posted net profit INR 47 crores for the period ended June 30, 2022 vs INR 160 crores during the same period ended June 30, 2021. Similarly, the EPS also dipped by 71% as it reported EPS of INR 2.96 for the period ended June 30, 2022. This vast dip was due to CDMO – Sterile Injectables and Generics as the segment was impacted by the pricing pressure in the US market and challenges related to import.